The world’s first potential therapy for an increasingly common, chronic lung condition has been identified following a trial ...

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups - read more about the latest trial ...

Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.

This finding not only provides a new treatment option for patients with bronchiectasis but also lays a solid foundation for the development of more targeted therapies in the future. This study ...

Metersky concludes, "This is a very promising new treatment and likely will be the first-ever FDA-approved treatment for ...

For further information, please contact Professor Dr Felix Ringshausen, [email protected], telephone (0511) 532-3595. The original paper ‘Phase 3 Trial of the DPP1 Inhibitor Brensocatib ...

"Brensocatib has the potential to transform the treatment landscape for bronchiectasis and we were pleased to receive the FDA acceptance of our NDA with priority review even earlier than ...

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers ...

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 ...

Drug developer Insmed has filed a new drug application with the FDA based on the data with hopes that brensocatib could become the first approved treatment for patients with bronchiectasis as well ...

Treatment with brensocatib also increased ... brensocatib could become the first approved treatment for patients with bronchiectasis as well as the first DPP-1 inhibitor. Brensocatib works on ...